Comment on case of benralizumab-induced exacerbations of chronic spontaneous urticaria
- PMID: 38634097
- PMCID: PMC11022288
- DOI: 10.1002/ccr3.8802
Comment on case of benralizumab-induced exacerbations of chronic spontaneous urticaria
Conflict of interest statement
None.
Similar articles
-
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial.Br J Dermatol. 2024 Feb 17:ljae067. doi: 10.1093/bjd/ljae067. Online ahead of print. Br J Dermatol. 2024. PMID: 38367194
-
Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review.Clin Rev Allergy Immunol. 2022 Dec;63(3):381-389. doi: 10.1007/s12016-022-08952-y. Epub 2022 Sep 1. Clin Rev Allergy Immunol. 2022. PMID: 36048326 Review.
-
Anti-IL-5 therapies for asthma.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834. doi: 10.1002/14651858.CD010834.pub4. Cochrane Database Syst Rev. 2022. PMID: 35838542 Free PMC article. Review.
-
Case of benralizumab-induced exacerbations of chronic spontaneous urticaria.Clin Case Rep. 2022 Jun 19;10(6):e05930. doi: 10.1002/ccr3.5930. eCollection 2022 Jun. Clin Case Rep. 2022. PMID: 35765284 Free PMC article.
-
Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints.Allergy. 2021 Apr;76(4):1277-1280. doi: 10.1111/all.14713. Epub 2020 Dec 28. Allergy. 2021. PMID: 33326617 No abstract available.
References
-
- 2023 GINA Main Report. Available from: https://ginasthma.org/wp‐content/uploads/2023/07/GINA‐2023‐Full‐report‐2....
LinkOut - more resources
Full Text Sources